NIAID proposed FY2017 initiative: Sustained Release of Antivirals for Treatment or Prevention

February 18, 2016

Oral therapy sustained-release strategies must have a window of effectiveness of at least 7 days from a single dose. Other approaches must have a minimal window of 30 days from a single dose (injection) or continuous dosing regimen (implant, transdermal patch, etc.). Sustained-release strategies for HIV prevention must have a minimum window of protection of 30 days from either a single dose (injection) or continuous dosing (implant, transdermal patch, etc.).